

(PS1483) PHASE I CLINICAL TRIAL OF CD19 CAR -T CELLS SECRETING PD-1-TARGETING IL-21 IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Topic: 02. Acute lymphoblastic leukemia - Clinical

Lei Lv¹, Meng Li¹, Jingjing Yang¹, Qingyang Liu^{*1}, Yanan Wen¹, Yu Jing¹, Liping Dou¹

¹The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China;

Background

Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) have an extremely poor prognosis. Although CD19-targeted CAR-T cell therapy can induce high initial response rates, T cell exhaustion often leads to relapse, with the PD-1/PD-L1 axis being a key mechanism.

Aims

This study aimed to evaluate the safety and efficacy of a novel bispecific armored CAR-T cell therapy (PZ04) for R/R B-ALL. These engineered cells constitutively secrete a PD-1Ab21 fusion entity, designed to locally block the immune checkpoint and enhance T-cell function.

Methods

This single-center, Phase I study (ChiCTR2300072572) enrolled 17 patients with R/R B-ALL. Patients received PZ04 cell infusion following lymphodepleting chemotherapy with an FC regimen (fludarabine/cytarabine). Primary endpoint was safety and the second endpoint was complete remission (CR) rate.

Results

The results demonstrated a CR rate of 81.3% (13/16), with all responders achieving minimal residual disease (MRD)-negative status. The 1-year overall survival (OS) rate was 53.0%. Among six patients with baseline central nervous system involvement, four (83.3%) achieved complete remission. Regarding safety, the incidence of grade ≥ 3 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) was 18.8% each (3/16 for each). No severe adverse events related to systemic immune checkpoint inhibitors were observed. Further analysis indicated a trend toward superior long-term survival in patients (n=6) who underwent consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy (1-year event-free survival 53.3% vs. 21.8%, P=0.075).

Summary/Conclusion

Conclusion: The bispecific CD19-targeted CAR-T cells secreting the PD-1Ab21 fusion entity (PZ04) demonstrate a high response rate and a manageable safety profile in patients with R/R B-ALL. Its innovative design provides a novel strategy to counteract T-cell exhaustion and shows potential as an effective bridge to transplantation. Larger studies are warranted to validate its long-term efficacy.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.